Tan Jia Yi, San Boon Jian, Ong Tze Ern, Yeo Yong Hao, Idowu Modupe
Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA,
Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Oncology. 2025 Mar 28:1-5. doi: 10.1159/000545459.
The incidence of multiple myeloma (MM) in the USA has been increasing over the past decades with persistent demographic disparities. Social determinants of health (SDOH) were found to affect health outcomes among certain diseases. However, there were limited data on the impact of SDOH on the MM mortality rates. Our study aimed to investigate the association between the SDOH and MM mortality rates from 2016 to 2020.
County-level data from the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry Social Vulnerability Index (CDC/ATSDR SVI) were correlated with MM mortality rates from the CDC WONDER database. Counties were categorized into four quartiles based on SVI scores: SVI-Q1 (lowest vulnerability) to SVI-Q4 (highest vulnerability). Age-adjusted mortality rates (AAMRs) per 100,000 individuals for patients aged 25 years and above were analyzed. The rate ratio (RR) was measured by calculating the ratio of the AAMRs in SVI-Q4 to SVI-Q1.
Between 2016 and 2020, 61,307 MM-related deaths occurred, with 20,390 in SVI-Q4 versus 8,498 in SVI-Q1. Overall, AAMR was higher in SVI-Q4 (4.90; 95% CI, 4.83-4.97) than in SVI-Q1 (4.66; 95% CI, 4.56-4.76), though the RR was not significant (1.05; 95% CI, 0.81-1.36). Higher SVI was not significantly associated with higher AAMR among males (RR: 1.03; 95% CI, 0.73-1.45) or females (RR: 1.10; 95% CI, 0.75-1.62). Among the younger patients (25-64 years old) and the older patients (65 years old and above), increasing SVI was not associated with higher AAMR (RR: 1.27 [95% CI, 0.69-2.34] and 1.01 [95% CI, 0.76-1.34], respectively). SVI was also not significantly associated with higher AAMR in the rural populations (1.07 [95% CI, 0.60-1.92]). Across racial groups - American Indians, Asians, African Americans, Hispanics, and Whites - SVI was not significantly associated with AAMR differences. Similarly, no significant differences were observed when stratified by census regions (Northeast, Midwest, South, and West).
African Americans had higher AAMRs from MM compared to other racial groups. However, SVI scores were not significantly associated with MM mortality disparities. These findings suggest that SVI alone is insufficient to determine mortality disparities in MM. Future research should explore more specific indicators to identify at-risk populations and address mortality inequities in MM.
在过去几十年中,美国多发性骨髓瘤(MM)的发病率一直在上升,且存在持续的人口统计学差异。健康的社会决定因素(SDOH)被发现会影响某些疾病的健康结果。然而,关于SDOH对MM死亡率影响的数据有限。我们的研究旨在调查2016年至2020年期间SDOH与MM死亡率之间的关联。
疾病控制和预防中心/有毒物质和疾病登记机构社会脆弱性指数(CDC/ATSDR SVI)的县级数据与来自CDC WONDER数据库的MM死亡率相关联。根据SVI分数,县被分为四个四分位数:SVI-Q1(最低脆弱性)至SVI-Q4(最高脆弱性)。分析了25岁及以上患者每10万人的年龄调整死亡率(AAMR)。通过计算SVI-Q4与SVI-Q1中AAMR的比率来测量率比(RR)。
2016年至2020年期间,发生了61307例与MM相关的死亡,其中SVI-Q4中有20390例,而SVI-Q1中有8498例。总体而言,SVI-Q4中的AAMR(4.90;95%CI,4.83-4.97)高于SVI-Q1中的AAMR(4.66;95%CI,4.56-4.76),尽管RR不显著(1.05;95%CI,0.81-1.36)。在男性(RR:1.03;95%CI,0.73-1.45)或女性(RR:1.10;95%CI,0.75-1.62)中,较高的SVI与较高的AAMR没有显著关联。在较年轻患者(25-64岁)和较年长患者(65岁及以上)中,SVI的增加与较高的AAMR没有关联(RR分别为1.27[95%CI,0.69-2.34]和1.01[95%CI,0.76-1.34])。SVI在农村人口中也与较高的AAMR没有显著关联(1.07[95%CI,0.60-1.92])。在不同种族群体——美洲印第安人、亚洲人、非裔美国人、西班牙裔和白人——中,SVI与AAMR差异没有显著关联。同样,按人口普查地区(东北部、中西部、南部和西部)分层时也未观察到显著差异。
与其他种族群体相比,非裔美国人的MM AAMR更高。然而,SVI分数与MM死亡率差异没有显著关联。这些发现表明,仅SVI不足以确定MM中的死亡率差异。未来的研究应探索更具体的指标,以识别高危人群并解决MM中的死亡率不平等问题。